@article {7810,
	title = {Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: A Hellenic Cooperative Oncology Group (HeCOG) study},
	journal = {Annals of Oncology},
	volume = {20},
	year = {2009},
	note = {Cited By :16Export Date: 21 February 2017},
	month = {2009},
	pages = {1362 - 1368},
	abstract = {Background: We undertook a randomized phase II trial to test whether the addition of paclitaxel (Taxol) to the cisplatin and ifosfamide (IP) combination could improve objective response (OR) rate, progression-free survival (PFS) and overall survival (OS) in patients with recurrent or metastatic cancer of the uterine cervix. Patients and methods: One hundred and fifty-three patients were randomly allocated to receive either the IP regimen (ifosfamide 1.5 g/m2, daily, on days 1-3 and cisplatin 70 mg/m2 on day 2) or the same combination with the addition of paclitaxel 175 mg/m2 on day 1 [ifosfamide, paclitaxel and cisplatinum (ITP) regimen]. Cycles were administered every 4 weeks on an outpatient basis. Results: A modest increase in neurotoxicity was observed with the triplet combination. OR rate was significantly higher in the ITP group (59\% versus 33\%, P = 0.002). Median PFS was 7.9 and 6.3 months for patients in the ITP and IP arms, respectively (P = 0.023). Median OS was 15.4 months and 13.2 months in the ITP and IP arms, respectively (P = 0.048). In multivariate analysis, the triplet yielded a hazard ratio of 0.70 for relapse or progression (P = 0.046) and 0.75 for death (P = 0.124) compared with the doublet. Conclusion: The ITP combination merits further investigation in randomized phase III studies. {\textcopyright} The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.},
	keywords = {Advanced cervical cancer, Cisplatinum, Ifosfamide, Neurotoxicity, Paclitaxel, Triplet combination},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-69449106007\&doi=10.1093\%2fannonc\%2fmdn797\&partnerID=40\&md5=d12bcf981bbab3150055cd09d87a1e03},
	author = {Mountzios, G. and Dimopoulos, M.A. and Bamias, A. and Vourli, G. and Kalofonos, H. and Aravantinos, G. and Fountzilas, G. and Papadimitriou, C.A.}
}
